Psychedelics face mixed evidence
The psychedelic‑therapy field is encountering rigorous scrutiny: meta‑analyses and trials show mixed results and persistent blinding concerns for psilocybin studies even as Helus Pharma’s SPL026 (IV DMT) hit its phase‑2a endpoint; separately, the largest review to date found no evidence that medicinal cannabis helps anxiety, depression, or PTSD. The landscape is shifting from hype to demands for stronger methods. (technologyreview.com) (psychiatrictimes.com) (sciencedaily.com)
A JAMA Network Open meta‑analysis pooled 17 acute‑phase randomized trials—psilocybin (n=373), esketamine (n=573) and SSRIs (n=4,014)—and found that control‑arm depression outcomes were significantly worse in the psilocybin trials than in the esketamine or SSRI trials. (jamanetwork.com)) The same meta‑analysis reported control‑arm MADRS response‑rate gaps of roughly 19% for psilocybin trials versus 33% for SSRI trials and 42% for esketamine trials, differences the authors flagged as large enough to inflate between‑group effect sizes. (ajmc.com)) Methodological literature has labeled the problem “functional unblinding” and recommended active‑placebo designs that meet five criteria—acute psychoactive and physiological effects, matched onset/duration, demonstrable safety, and no target‑disease benefit—to protect blinding integrity. (academic.oup.com)) Helus Pharma’s randomized Phase‑2a IV‑DMT paper was published in Nature Medicine and reported a mean MADRS difference of −7.35 in favor of SPL026 at two weeks, with symptom reductions observed within one week and many participants maintaining benefit at three months; the trial listed 66 enrollees on ClinicalTrials.gov. (nature.com)) The SPL026 program describes the compound as an intravenous, short‑acting DMT fumarate and the Nature Medicine report characterizes the study as among the first randomized, placebo‑controlled trials of a short‑acting psychedelic formulation in moderate‑to‑severe MDD. (nature.com)) A Lancet Psychiatry systematic review and meta‑analysis of 54 randomized controlled trials published in March 2026 synthesized data from 2,477 participants and reported that available RCT evidence does not support cannabinoid efficacy for anxiety, depression, or PTSD while noting risks such as increased psychotic symptoms and cannabis‑use disorder. (thelancet.com)) Those converging signals—rigorous positive phase‑2 data for an IV DMT but meta‑analyses exposing weak control responses and null cannabinoid findings—have prompted calls in commentaries and methodological reviews for larger randomized trials, pre‑specified blinding assessments, and the routine use of validated active placebos in future psychedelic research. (technologyreview.com))
